Skip to main content
Equibles
IRWD logo

IRWD · Ironwood Pharmaceuticals Inc

Track IRWD — free

Use IRWD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research IRWD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.76 -0.01 (-0.13%)
Russell 2000 member Rebalance outlook locked
Market Cap
$682.44M
Shares
165.24M
Volume · Oct 2 361.06K Avg daily vol (3M) 2.11M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.76 Open$3.95 Day$3.74–3.97 52W close$1.43–5.39 Avg vol 30d1.9M Short int18.7M · 11.3% float · 13.1d Short vol55% Last earningsAug 6, 2026 DataJan 2020–Oct 2026 Filing10-Q · Aug 6

Up next

Next earnings call
Nov 16, 2026 Est · unconfirmed · in 6 wks
Latest filing: 10-Q
filed Aug 6, 2026
Q1 2026 earnings call transcript
call held May 7, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$389.32M
Trailing 12 months
Net income (TTM)
$129.87M
Trailing 12 months
Revenue growth YoY
+32.6%
Year over year
Operating margin
60.1%
Trailing 12 months
P / E (TTM)
5.2
Trailing earnings · reciprocal yield 19.4%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-5.5%
Year over year · fewer shares
Price change (1Y)
+203.1%
Trailing year
Short interest
11.3%
Latest settlement · 13.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Neutral Sentiment Bearish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 16.4 · calm Equity put/call 0.57
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −6%
below
Price vs 50-day avg −10%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 59%
mid-range
Momentum
relative strength
Neutral
1-month return −15%
trailing
6-month return +4%
trailing
YTD return +12%
this year
Relative strength −9%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Distributing
-7% holders QoQ · +24 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.33% of float · ▲ +6.1% MoM · 13.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
212 holders — mid 3-yr range
Squeeze score 67
elevated · 0–100
Fundamentals
Excellent
Revenue growth +9%
Y/Y
EPS growth +1400%
Y/Y
Free cash flow $127.0M
Valuation P/E 5.4
below peers
Buyback $32.4M
remaining
Balance sheet $110.4M
net debt
Quant / Vol
risk profile
Very High
Volatility 94%
annualized · 1-yr
Max drawdown −44%
past year
ATR 5.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 4
Latest guidance · from the 8-K filed Aug 6, 2026
Adjusted EBITDA · 2026 Non-GAAP at least $310M
Guided vs delivered · last 4 settled
Total Revenue FY 2024
guided $350M – $375M
$351.41M In line
Total Revenue 2023
guided $435M – $450M
$442.74M In line
Total Ironwood revenue 2021
guided $390M – $410M
$413.75M Beat +3.4%
Total Ironwood revenue for the year
guided $360M – $380M
$389.52M Beat +5.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−6% Bearish
Price vs 50-day avg
−10% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
59% Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow Distributing
-7% holders QoQ · +24 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
11.33% of float · ▲ +6.1% MoM · 13.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
212 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $4 · 59% Range high $5
vs 200-day avg -6% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
IRWD
Ironwood Pharmaceuticals Inc
this stock
$682.44M +11.6% +8.9% 5.4 11.3%
TAK
Takeda Pharmaceutical Co Ltd
 $60.23B +14.6% — — 0.1%
GALDY
Galderma Group AG/ADR
 $46.00B -6.4% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $45.67B +26.0% +4.3% 64.3 2.7%
HLN
Haleon plc
 $40.72B -13.7% — — 0.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
212
% held
97.6%
Net QoQ
-12.0M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
228
View
Short & Settlement
Short Interest Rising
Shares short
18.7M
Days to cover
13.1d
Change
+1.1M sh
View
Short Volume
Short vol %
55%
As of
Oct 1, 2026
Short Total
View
Fails to Deliver
FTD shares
211
Value
$905
As of
Sep 4, 2026
View
Off-Exchange
Off-exchange %
43.4%
Week of
Aug 24, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$296.2M
Net income (FY)
$24.0M
EPS diluted
$0.15
View
Buybacks
Authorized
$150.0M
Remaining
$32.4M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 6, 2026
This year
15
View
Proposed Sales
Value
$377.4K
Shares
83.3K
Filed
Sep 23, 2026
View
Earnings & Events
Webcasts
Last webcast
Aug 6, 2026
View
Investor Relations
Latest news
Ironwood Appoints Dr. Jeffrey Sil…
Published
Jul 14, 2026
View

Performance

5D 20D 120D MTD YTD
IRWD -10.3% -14.7% +3.6% -5.3% +11.6%
SPY -0.4% -0.2% +12.4% +0.2% +12.0%
vs SPY -9.8% -14.6% -8.9% -5.5% -0.5%

Capital returns

Buyback program · as of Mar 31, 2022
Authorized
$150.00M
Spent (derived)
$117.60M
Remaining
$32.40M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1446847 CUSIP 46333X108 13F (30d) 5 filings 5 filers Visit website Investor relations